BLOG

Gene therapy for wet AMD ‘on the horizon’

In the OPTIC trial, patients with wet age-related macular degeneration who were treated with ADVM-022, an intravitreal gene therapy, did not require additional injections following treatment, according to a presenter at the American Academy of Ophthalmology annual meeting.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}